Accurate quantification of infarct volume in the Middle Cerebral Artery Occlusion (MCAO NHP models) is a critical endpoint in translational stroke research. It directly supports the evaluation of disease severity, therapeutic efficacy, and the predictive value of preclinical findings for clinical outcomes. Compared with rodent models, NHP MCAO models provide closer anatomical and physiological relevance to humans, particularly in cerebrovascular architecture and neurofunctional organization. Therefore, robust and standardized infarct volume measurement is essential to fully leverage the translational value of this model.
Importance of Infarct Volume Measurement in MCAO NHP Models
Infarct volume serves as a quantitative biomarker of ischemic brain injury. In NHP studies, where study size is limited and variability must be controlled, precise infarct quantification is particularly important for statistical robustness and data interpretation. It is commonly used to:
- Assessment of Severity: Evaluate the spatial distribution of cerebral ischemia across brain regions.
- Therapeutic Efficacy: Measure pharmacological or interventional treatment success by reduction in lesion size.
- Functional Correlation: Correlate structural damage with behavioral analysis outcomes.
- Clinical Translation: Support dose selection and provide evidence for human clinical trial designs.
Methods for Measuring Infarct Volume
Magnetic Resonance Imaging (MRI)
MRI is the primary method for longitudinal, non-invasive infarct assessment. Key sequences include Diffusion-weighted imaging (DWI) for early detection and T2-weighted imaging for mature infarcts. The quantification workflow involves slice-by-slice segmentation using validated software to calculate total volume by integrating lesion areas across defined slice thicknesses.
Histological Assessment
Histological staining remains the reference method for endpoint validation. Common approaches include TTC staining to differentiate viable tissue from pale infarcted regions, and H&E staining for cellular-level characterization. While accurate, this is a terminal procedure and cannot provide longitudinal data.
Positron Emission Tomography (PET)
PET provides complementary functional assessment using tracers like FDG for glucose metabolism. It helps identify the ischemic penumbra-tissue that is metabolically impaired but potentially salvageable. It is typically used in combination with MRI for integrated structural-functional analysis.
Key Considerations for Accurate Measurement
Achieving precision in large animal models requires rigorous control over technical variables. The following factors are critical for high-quality data:
- Standardization: Consistency in imaging protocols, timing, and resolution across all study cohorts.
- Edema Correction: Applying swelling-adjusted volume calculations to prevent overestimation during the acute phase.
- Multimodal Integration: Interpreting structural data alongside clinical-grade MRI, CT, and PET-CT systems data for a holistic view of brain health.
Prisys Platform Capabilities in Infarct Volume Assessment
At Prisys Biotech, infarct volume measurement is integrated into a comprehensive NHP translational CNS research platform. We utilize advanced neuroimaging sequences and a dedicated team of radiology experts with clinical experience. Our platform supports longitudinal infarct tracking, quantitative lesion analysis, and seamless alignment with clinical imaging endpoints, ensuring that preclinical data is robust enough for regulatory submission.
FAQ
Q: What is the most reliable method to measure infarct volume in MCAO NHP models?
A: MRI is the most reliable method for longitudinal studies due to its non-invasive nature and high spatial resolution. Histology is typically used as a terminal validation method.
Q: Why is infarct volume measurement more critical in NHP models than in rodents?
A: NHP studies usually involve smaller sample sizes and higher costs. Therefore, precise and reproducible infarct quantification is essential to ensure statistical power and translational relevance.
Q: How can variability in infarct volume measurement be reduced?
A: Variability can be minimized through standardized imaging protocols, consistent segmentation criteria, regular system calibration, and integration of automated image analysis tools.
References
1. Cook, D. J., & Tyson, G. W. (2014). Nonhuman Primate Models of Stroke. In Animal Models of Acute Neurological Injuries.
2. Liu, F., et al. (2020). Standardized Neuroimaging Protocols for Ischemic Stroke in Macaque Models. Journal of Cerebral Blood Flow & Metabolism.
